Kolexia
Ghez David Hématologie
Ghez David
Hématologie
Gustave-Roussy
Villejuif, France
135 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Leucémies Lymphome B Maladie de Hodgkin Leucémie chronique lymphocytaire à cellules B Lymphome B diffus à grandes cellules Leucémie aigüe myéloïde Lymphome malin non hodgkinien Myélome multiple

Collaborateurs

Voir plus
Lazarovici Julien
Lazarovici Julien
Ch Prive De L Europe, Le Port-Marly, France
Danu Alina
Danu Alina
Gustave-Roussy, Villejuif, France
Ribrag Vincent
Ribrag Vincent
Gustave-Roussy, Villejuif, France
Michot Jean-Marie
Michot Jean-Marie
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Abbvie
13 collaboration(s)
Dernière en 2023
Amgen
6 collaboration(s)
Dernière en 2023
Janssen
6 collaboration(s)
Dernière en 2022
AstraZeneca
5 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome: A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm
Essai Clinique (M.D. Anderson Cancer Center)   03 janvier 2024
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
Frontiers in immunology   18 octobre 2023
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread: A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
Essai Clinique (BMS)   27 septembre 2023
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia -ITD patients.
Haematologica   01 septembre 2023
Retrospective analysis of a cohort of 41 B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).
Haematologica   01 juin 2023
Crystal-storing lymphocytosis.
American journal of hematology   10 mai 2023
Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   06 mai 2023
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.
Immunotherapy   23 mars 2023
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (Relatlimab, BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies
Essai Clinique (BMS)   20 mars 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
American journal of hematology   18 janvier 2023